Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IOBT 
IO Biotech Inc (IOBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.8
1 Year Target Price $4.8
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.24% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.48M USD | Price to earnings Ratio - | 1Y Target Price 4.8 |
Price to earnings Ratio - | 1Y Target Price 4.8 | ||
Volume (30-day avg) 5 | Beta 0.21 | 52 Weeks Range 0.32 - 2.79 | Updated Date 10/17/2025 |
52 Weeks Range 0.32 - 2.79 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.63% | Return on Equity (TTM) -212.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8883197 | Price to Sales(TTM) - |
Enterprise Value 8883197 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880914 | Shares Floating 34636891 |
Shares Outstanding 65880914 | Shares Floating 34636891 | ||
Percent Insiders 0.34 | Percent Institutions 63.84 |
Upturn AI SWOT
IO Biotech Inc
Company Overview
History and Background
IO Biotech, Inc. is a clinical-stage biopharmaceutical company founded in 2013. It focuses on developing immune-oncology therapies based on its T-winu00ae technology platform to fight cancer.
Core Business Areas
- Immuno-Oncology Drug Development: Focuses on discovering and developing novel immunotherapies targeting cancer.
- T-win Platform: Their novel technology platform which works by stimulating T cells.
Leadership and Structure
Dr. Mai-Britt Zocca is the CEO. The company has a typical organizational structure for a biotech company, with departments focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- IO102-IO103: A combination therapy targeting IDO and PD-L1. Currently in clinical development for multiple cancers. Competitors include companies developing IDO inhibitors and PD-L1 inhibitors, such as Bristol Myers Squibb (OPDIVO) and Merck (KEYTRUDA). No concrete data available for market share, as still in trial phase.
- IO202: An immune-modulatory vaccine designed to target immunosuppressive cells. This is pre-clinical. Competitors are any vaccine companies or similar immunosuppressive cell therapies. No concrete data available for market share, as still in trial phase.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by the success of checkpoint inhibitors and the increasing understanding of cancer immunology. Key trends include combination therapies, personalized medicine, and new target discovery.
Positioning
IO Biotech is positioned as a clinical-stage company with a focus on innovative combination therapies targeting key immunosuppressive pathways. Their T-win platform represents a potential competitive advantage.
Total Addressable Market (TAM)
The immuno-oncology market is estimated to be worth hundreds of billions of dollars. IO Biotech is targeting specific cancer types within this broader market. The size of the TAM depends on the specific indication and the success of the drug development.
Upturn SWOT Analysis
Strengths
- Novel T-win platform
- Promising clinical data for IO102-IO103
- Experienced management team
- Focus on combination therapies
Weaknesses
- Clinical-stage company with no approved products
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High risk of drug development failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results leading to regulatory approval
- Increasing demand for innovative cancer therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- AstraZeneca (AZN)
Competitive Landscape
IO Biotech is a smaller player competing against large pharmaceutical companies. Its success depends on the differentiation and efficacy of its T-win platform and drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's advancement of its clinical pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing IO102-IO103 into later-stage clinical trials and expanding the T-win platform.
Summary
IO Biotech is a clinical-stage immuno-oncology company with a novel T-win platform. It is focusing on combination therapies for cancer. Its strengths lie in its promising clinical data and experienced management. However, it faces risks related to clinical trial outcomes and competition from larger pharmaceutical companies, and needs funding to get through trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IO Biotech Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share data is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IO Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | Founder, President, CEO, Principal Financial Officer & Director Dr. Mai-Britt Zocca Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.iobiotech.com |
Full time employees 78 | Website https://www.iobiotech.com | ||
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.